Are the cardiovascular risk reductions seen with empagliflozin in the EMPA-REG OUTCOME trial explained by conventional cardiovascular risk factors?
To estimate the degree to which cardiovascular risk reductions demonstrated with empagliflozin administration in the EMPA-REG OUTCOME trial might be explained by changes observed in conventional cardiovascular factors during the study.
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Conference item |
| Published: |
Wiley
2017
|